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Abstract Human tissue allografts are widely used in
a variety of clinical applications with over 1.5 million
implants annually in the US alone. Since the 1990s,
most clinically available allografts have been disinfec-
ted to minimize risk of disease transmission. Additional
safety assurance can be provided by terminal steriliza-
tion using low dose gamma irradiation. The impact of
such irradiation processing at low temperatures on
viruses was the subject of this study. In particular, both
human tendon and cortical bone samples were seeded
with a designed array of viruses and the ability of
gamma irradiation to inactivate those viruses was
tested. The irradiation exposures for the samples
packed in dry ice were 11.6–12.9 kGy for tendon and
11.6–12.3 kGy for bone, respectively. The viruses,
virus types, and log reductions on seeded tendon and
bone tissue, respectively, were as follows: Human
Immunodeficiency Virus (RNA, enveloped),[2.90 and
[3.20; Porcine Parvovirus (DNA, non-enveloped),
1.90 and 1.58; Pseudorabies Virus (DNA, enveloped),
3.80 and 3.79; Bovine Viral Diarrhea Virus (RNA,
enveloped), 2.57 and 4.56; and Hepatitis A Virus
(RNA, non-enveloped), 2.54 and 2.49, respectively.
While proper donor screening, aseptic technique, and
current disinfection practices all help reduce the risk of
viral transmission from human allograft tissues, data
presented here indicate that terminal sterilization using
a low temperature, low dose gamma irradiation process
inactivates both enveloped and non-enveloped viruses
containing either DNA or RNA, thus providing addi-
tional assurance of safety from viral transmission.
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Abbreviations
AATB American association of tissue banks
BVDV Bovine viral diarrhea virus
CDC Center for disease control
D10 In this context, the radiation dose required
for one log reduction of viral load
DNA Deoxyribonucleic acid
FrhK-4 Fetal rhesus monkey kidney
HAV Hepatitis A virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus




SAL Sterility assurance level
Introduction
Human tissue allografts are widely used in a variety
of clinical applications. In particular, the use of bone
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and soft tissue allografts for orthopedic repair has
gained wide acceptance over the past two decades
(Zhang et al. 1994; Peterson et al. 2001; Fanelli et al.
1996; Gasser and Uppal 2006; Mirzayan 2005). The
American Association of Orthopedic Surgeons esti-
mates that over 1.5 million musculoskeletal allografts
are used annually (Joyce et al. 2008). Since the
1990s, most clinically available allografts have been
disinfected to minimize risk of disease transmission.
However, disease transmission is still a risk as
highlighted by a 2002 Center for Disease Control
(CDC) investigation which identified twenty-six
cases of bacterial infections that stemmed from
allograft tissue, one of which resulted in the death
of a 23-year-old man (Jones et al. 2007; Grieb et al.
2006; Vangsness et al. 2006; CDC report 2002;
Kainer et al. 2004). The perceived risk of postoper-
ative infection is noted by several authors as the
single largest potential disadvantage in choosing an
allograft (McGuire and Hendricks 2009; Shino et al.
2002). While risk of infection or disease transmission
is thought to be a major disadvantage of allografts, an
American Academy of Orthopedic Surgeons tissue
work group (Joyce et al. 2008), reports ‘‘Disease
transmission is rare when comparing reports of
infection versus number of allografts distributed/
yr.’’ The tissue banking community has responded to
the remaining risk by developing methods to termi-
nally sterilize allograft tissues in their final package
(Joyce et al. 2008). The provision of sterile allograft
tissue, which is practiced by some tissue banks, can
be accomplished by following several steps which
include donor screening, microbiological testing,
aseptic recovery and processing, disinfection, and,
finally, terminal sterilization (McAllister et al. 2007).
These processes can be validated to yield a microbial
sterility assurance level (SAL) of 10-6 at a low dose
of irradiation (Baker et al. 2005; Moore et al. 2004;
Nguyen et al. 2011). An SAL of 10-6 indicates there
is a 1 out of 1,000,000 chance that a viable organism
exists with any single graft (Vangsness et al. 2003).
Achieving this SAL by a validated process allows
labeling of terminally sterilized allografts as sterile
(ANSI/AAMI 2008). To address clinical effective-
ness, this terminal irradiation sterilization process has
also been demonstrated to have no significant impact
on biomechanical or biological properties (Balsly
et al. 2008; McGilvray et al. 2005; Greaves et al.
2008; Goertzen et al. 1995; Rihn et al. 2006).
In addition to microbial sterility, however, the
elimination of viruses is essential in assuring tissue
safety. In March of 2005, the American Association
of Tissue Banks (AATB) sought to further reduce the
risks of Human Immunodeficiency Virus (HIV) and
Hepatitis C Virus (HCV) transmission by requiring
nucleic acid testing (NAT) in donor screening
procedures (Rigney 2004). NAT has been shown to
markedly reduce the window period of these viruses
and was incorporated into blood banking procedures,
effectively reducing the risk of HIV and HCV
transmission from 1 in 1.5 million blood units and
1 in 276,000 blood units, respectively, to 1 in
2 million blood units for either virus (Stramer et al.
2004). Also, the introduction of NAT has halved the
window period for HIV-1 to 12 days from the
previous 22 day antibody window (McGuire and
Hendricks 2009). Encouragingly, one report indicates
that no instances of viral transmission are reported to
have ever occurred from tissue processed following
proper donor screening procedures that include HIV
testing (Peterson et al. 2001). While NAT screening
reduces viral risks, these methods only address
specific viruses. Previously Chen (2008) described
the impact of disinfection processing solutions (US
Patents 5,556,379; 5,820,581; 5,977,034; 6,024,735)
on a variety of enveloped and non-enveloped viruses.
While these processes, in addition to proper screening
and NAT, greatly reduce any risk of viral transmis-
sion, terminal sterilization has the potential to provide
greater assurance of viral safety. Specifically, gamma
irradiation has been demonstrated to lead to viral
inactivation even at low dosages. (Campbell et al.
1994; Conway et al. 1991; Dugan and Trujillo 1975;
Fideler et al. 1995; Grecz et al. 1987; Grieb et al.
2005, 2006; House et al. 1990; Kaupert et al. 1999;
Miekka et al. 1998; Pelka et al. 1993; Pruss et al.
2002; Sullivan et al. 1973; Thomas et al. 1982).
However indicative, these studies were not compre-
hensive to the wide array of target viruses, tissues,
and desired irradiation conditions.
While these numerous studies all addressed vari-
ous viruses and conditions, we sought to perform a
comprehensive assessment of the impact of gamma
irradiation at low temperatures on both seeded human
tendon and cortical bone and to examine a designed
array of viruses in a single study. Low temperature
irradiation exposure was chosen as this has previ-
ously been shown to minimize free radical generation
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and tissue damage (Anderson et al. 1992; Hamer
et al. 1999). Viruses were chosen to represent an
array of enveloped, non-enveloped, RNA, and DNA
viruses, and included Human Immunodeficiency
Virus (HIV), Porcine Parvovirus (PPV), Pseudorabies
Virus (PrV), Bovine Viral Diarrhea Virus (BVDV),
and Hepatitis A Virus (HAV). Here, the hypothesis
that low temperature gamma irradiation of seeded
human tendon and bone would result in the reduction
of a comprehensive array of RNA, DNA, enveloped,
and non-enveloped viruses was tested.
Methods
The study design was to separately seed tendon and
bone human tissues with a designed array of viruses
and then subject the separate tissues to low temper-
ature, low dose gamma irradiation, and test for
surviving viruses. Human tibialis tendons and cortical
bone derived from long bones were obtained with
generous research authorization. Tendon and cortical
bone used in the study came from multiple donor
sources. Bone tissue was from two male donors, ages
55 and 77. Tendon was from two male and two female
donors, ages 20, 55, 64, and 64, respectively. How-
ever, to provide internal control, each individual virus
tested per tissue type was tested with a single donor
tissue. As an example, all tests for recovery, interfer-
ence, toxicity, viral reduction, and time = 0 controls
to test, e.g., HIV with tendon were perform using
individual tendon samples from a single donor. Prior
to use, all donors were serologically screened by
either antibody or nucleic acid testing and the absence
of the following agents was confirmed: Hepatitis B,
Hepatitis C, HIV, and HTLV. The individual tissue
portions tested consisted of a single, intact cortical
bone piece or tendon segment, respectively. Prior to
seeding and irradiation, tissues were processed using
the Allowash disinfection technology (US Patents
5,556,379; 5,820,581; 5,977,034; 6,024,735) to mimic
the anticipated tissue condition prior to terminal
irradiation. In order to perform a comprehensive
study, an array of viruses was tested to include every
permutation of DNA, RNA, enveloped, and non-
enveloped characteristics. In addition, a specific
environmentally relevant virus (HIV) was included.
The viruses tested thus included: HIV, HTLV-IIIB
strain, an 80–130 nm enveloped RNA containing
retrovirus; PPV, NADL-2 strain, an 18–26 nm, non-
enveloped, DNA-containing parvovirus; PrV, SHOPE
strain, a 150–200 nm, enveloped, DNA-containing
virus; BVDV, Singer strain, a 50–70 nm, enveloped
RNA-containing pestivirus; and HAV, HM175 strain,
18f, a 28–30 nm, non-enveloped, RNA-containing
picornavirus. To qualify the test methodology, toxic-
ity and interference studies were performed at the
testing facility (Wuxi Apptec, Philadelphia, PA). To
prepare samples for indicator cell toxicity, 1 g tissue
portions were mock-spiked with 0.5 mL of virus
suspension media and allowed to absorb into the
tissue for 15 min at 2–8C, followed by tissue
homogenization (tendon) or suspension (bone) in a
total of 9.5 mL of virus resuspension media. Serial
dilutions (in serum-free media) of this solution were
tested for toxicity against the virus indicator cell lines
appropriate for each virus (see Table 1). Serial
dilutions (in serum-free media) of this solution were
tested for toxicity against the virus indicator cell lines
appropriate for each virus (see Table 1). Cell
Table 1 Viral reduction-human tendon (all values in log)
Virus HIV PPV PrV BVDV HAV
Indicator cell line CEM-A ST CV-1 BT FrhK-4
Titer-seeded 6.84 6.72 7.06 7.82 8.40
Gamma-To 5.47 5.96 5.77 7.23 7.89
Gamma-treated \2.57 4.06 1.97 4.66 5.35
Total log reduction [2.90 1.90 3.80 2.57 2.54
Approximate D10 value \4 6 3 5 5
Viral reduction of seeded human tendon treated with gamma irradiation at low temperatures. Shown are the indicator cell lines, titer
seeded onto allograft, titer of recovered virus from seeded grafts (Gamma-T0), titer of recovered virus from seeded and irradiated
grafts (Gamma-T0), and total log reduction (Gamma-T0 minus Gamma-treated). Also shown is a rounded approximate D10 value
calculated by dividing the 11.6–12.9 kGy dose by the total log reduction and assuming a linear dose–response relationship
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monolayers were read by visually evaluating the
percentage of monolayer remaining per surface area
of the well. No toxicity was observed in the negative
control wells; therefore 100% of the monolayer was
present and intact. For the test sample, if toxicity was
observed (i.e., a percentage of that monolayer was
missing), that percentage was determined visually by
comparison to the negative control. One technician
determined the percentage of cytotoxicity (if any) and
a second operator was required for verification.
Samples which reduced the cell numbers below 80%
of controls were considered toxic. Extracts prepared
to test interference were likewise prepared, followed
by dilution to a non-toxic level, as determined by the
toxicity assay. Then, samples were spiked to 5% v/v
with virus stock solution. Controls consisted of serum-
free media also spiked to 5% v/v with virus stock
solution. Samples which altered the virus titer by[0.5
log10 were considered to interfere. The experimental
groups (Gamma-treated), were prepared by seeding
0.5 mL of a high titer viral solution (see Tables 1, 2)
on 1 g of tissue and allowing absorption for 15 min at
2–8C. These tissues were placed into a container on
dry ice and shipped for irradiation using a 60Co source
(Steris, Morton Grove, IL). The irradiation was
performed while the samples were still stored on dry
ice to maintain low temperatures. The container had
previously been mapped for internal irradiation dos-
age under processing conditions in order to accurately
measure tissue exposure. Following irradiation at
11.6–12.3 kGy for cortical bone or 11.6–12.9 kGy for
tendon, respectively, the samples were returned to the
testing facility and maintained at or below -60C
until viral testing. For testing, the 1 g samples were
homogenized (tendon) or suspended (bone) in a total
of 9.5 mL virus resuspension media. A portion was
diluted to non-toxic and non-interfering levels, as
determined by toxicity and interference testing, seri-
ally diluted, and infectivity determined in the appro-
priate indicator cell line (see Table 1). Controls
(Gamma-To) were similarly seeded, extracted as
above, and samples maintained at or below -60C
until final testing along with the test groups.
Results
The test methods were qualified using methods
described in the ‘‘Methods’’ section and no interfer-
ence or toxicity was noted towards any of the viruses
at the experimentally pertinent dilution levels. In
detail, no tissue extracts were found to be toxic to
indicator cells at greater than a 10-fold dilution. All
test article extracts were diluted 20-fold for final
titers, which was beyond any lower level of dilution
which may have exhibited toxicity. Likewise, no
diluted tissue extracts exhibited interference at
greater than a threefold dilution, again, which was a
lower level of dilution than the 20-fold dilution used
for all test article extracts. In-process dosimetry
verified the dose range at 11.6–12.3 kGy for cortical
bone samples and 11.6–12.9 kGy for tendon samples.
Following seeding and gamma irradiation, the sam-
ples were tested as described. Three readings were
taken per test sample. The log quantities of virus
extracted from controls to gamma irradiated samples,
as well as the seeding titer, are shown for tendon
(Table 1) and bone (Table 2), respectively. In addi-
tion, rounded D10 value for the various viruses are
also shown in Tables 1 and 2. Total log reduction was
Table 2 Viral reduction human cortical bone (all values in log)
Virus HIV PPV PrV BVDV HAV
Indicator cell line CEM-A ST CV-1 BT FrhK-4
Titer-seeded 6.92 7.30 8.17 7.11 8.12
Gamma-To 5.77 7.11 8.01 7.01 8.28
Gamma-treated \2.57 5.53 4.22 2.45 5.79
Total log reduction [3.20 1.58 3.79 4.56 2.49
Approximate D10 value \4 8 3 3 5
Viral reduction of seeded human cortical bone treated with gamma irradiation at low temperatures. Shown are the indicator cell lines,
titer seeded onto allograft, titer of recovered virus from seeded grafts (Gamma-T0), titer of recovered virus from seeded and irradiated
grafts (Gamma-T0), and total log reduction (Gamma-T0 minus Gamma-treated). Also shown is a rounded approximate D10 value
calculated by dividing the 11.6–12.3 kGy dose by the total log reduction and assuming a linear dose–response relationship
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considered the difference between the Gamma-To and
Gamma-treated sample titers. The irradiation dose
tested, in the range of 11.6–12.9 kGy, yielded an
approximate 2–5 log reduction of the various viruses
tested, as summarized in Table 3. In detail, the
viruses, virus types, and log reductions on seeded
tendon and bone tissue, respectively, were as follows:
HIV (RNA, enveloped), [2.90 and [3.20; PPV
(DNA, non-enveloped), 1.90 and 1.58; PrV (DNA,
enveloped), 3.80 and 3.79; BVDV (RNA, enveloped),
2.57 and 4.56; and HAV (RNA, non-enveloped), 2.54
and 2.49, respectively. Thus, the hypothesis is proven
that a low temperature, gamma irradiation process
will inactivate DNA, RNA, enveloped, and non-
enveloped viruses.
Discussion
The increased use of allograft tissue for musculo-
skeletal repair has brought more focus to the safety of
allogeneic tissue and the efficacy of various sterili-
zation techniques. As previously mentioned, the
provision of sterile allograft tissue can be accom-
plished by following several steps which include
donor screening, microbiological testing, aseptic
recovery and processing, disinfection, and terminal
sterilization (McAllister et al. 2007). One such
method of terminal sterilization is gamma irradiation;
which can provide both bactericidal and virucidal
effects via direct alteration of nucleic acids leading to
infectious agent dysfunction and destruction (Vangs-
ness et al. 2003). Of particular interest, numerous
reports indicate the inactivation of HIV with gamma
irradiation (Campbell et al. 1994; Conway et al.
1991; Conway and Tomford 1992; Hiemstra et al.
1991; Pruss et al. 2002; Salai et al. 1997; Sullivan
et al. 1973). While a few studies have concluded that
at least 30 kGy of gamma irradiation is needed to
inactivate HIV (Fideler et al. 1994; Hernigou et al.
2000), these reports have assumed HIV is present in
high density levels. While 30 kGy may be necessary
to inactivate high-density amounts of HIV, it is
excessive for lower density levels of the virus that
might be found, if at all, in medically screened, NAT
tested, and disinfectant processed tissue. In example,
Conway et al report a D-10 value for HIV of
approximately 4 kGy indicating a potential termi-
nally sterilizing dose of 12 or 16 kGy would yield 3
or 4 log reduction of HIV. Again, the likelihood of
any virus, much less large quantities following proper
donor eligibility, medical history, and NAT testing is
remote to begin with. As demonstrated here, an
irradiation dose of 11.6–12.9 kGy administered at
low temperature yields an approximate 2–5 log
reduction of the various viruses tested including a
minimum of 3 log reduction of HIV seeded on both
tendon and bone tissues. Please note that this
irradiation dosage may be at or below an actual dose
used by a manufacturer to achieve terminal steriliza-
tion, and thus these values may be considered a worst
case situation for log inactivation. To illustrate, if an
allograft provider were to sterilize tissue at, e.g.,
17.4–19.4 kGy (a 50% higher dose than used in the
study reported here) then the anticipated log reduc-
tion would rise 50% as well. This is significant as
current allograft terminal sterilization methods may
range from just over 10 kGy up to as much as 50 kGy
(Block 2006). An additional reason for including a
terminal irradiation step in allograft processing is to
safeguard against those viruses which are currently
not tested or are unknown. A study limitation is that
individual tests were performed with a single sample
of material. While this hampers any conclusion of
Table 3 Virus test groups and log viral inactivation summary
Virus Nucleic acid Virus type Bone Tendon
Human immunodeficiency virus (HIV) RNA Enveloped [3.20 [2.90
Porcine parvovirus (PPV) DNA Non-enveloped 1.58 1.90
Pseudorabies virus (PrV) DNA Enveloped 3.79 3.80
Bovine viral diarrhea virus (BVDV) RNA Enveloped 4.56 2.57
Hepatitis A virus (HAV) RNA Non-enveloped 2.49 2.54
Total log reduction of viruses seeded on human tissue by gamma irradiation. Note the variety of viruses used including all
permutations of DNA, RNA, enveloped, and non-enveloped viruses. The total log reduction as calculated in Tables 1 and 2 is
summarized
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statistical significance, note that accompanying con-
trols (recovery, toxicity, and interference tests) were
performed with tissue from the same donor to provide
internal control. In addition, multiple readings were
taken of each test sample increasing confidence in
results. Another study limitation is the use of small
tissue samples (1 g) and not whole bone or tendon
allografts. While whole allografts would have been
impractical to test, the relative viral load can be
extrapolated from the small samples to a large graft.
Enhancing the validity of the study, however, is that
the test inactivation agent studied here is gamma
irradiation which will fully penetrate tissue and is
thus not dependent on tissue size or dimension.
Conclusion
Terminal sterilization of human allograft tissue using
a low dose gamma irradiation process inactivates
both enveloped and non-enveloped viruses containing
either DNA or RNA. This final step in the processing
of human allografts complements prior steps in
providing additional assurance of viral safety.
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